Inclusion Criteria:

          -  Non-small cell lung cancer (NSCLC) Cohort: Histologically or cytologically confirmed
             diagnosis of NSCLC that is locally advanced or metastatic; No activating EGFR
             mutations, ALK or ROS1 translocations/rearrangements where testing is standard of
             care; received at least 1 prior platinum-based chemotherapy regimen for locally
             advanced or metastatic NSCLC; No more than 2 prior lines of systemic therapy for
             locally advanced or metastatic disease (If disease progression occurred during or
             within 6 months after neoadjuvant/adjuvant chemotherapy or radiotherapy-chemotherapy,
             the regimen is counted as 1 prior treatment regimen towards the allowed limit of prior
             treatment regimens); Checkpoint inhibitor naïve.

          -  Urothelial Cancer (UC) Cohort: Histologically or cytologically confirmed diagnosis of
             transitional cell carcinoma (TCC) of the urothelium (if mixed, more than 50% TCC
             component) including bladder, urethra, ureters, or renal pelvis that is locally
             advanced or metastatic; No prior systemic treatment for locally advanced or metastatic
             disease; Prior neoadjuvant or adjuvant therapy is permitted if disease progression
             occurred >12 months after the completion of therapy; Checkpoint inhibitor naïve;
             Ineligible for receiving cisplatin-containing front-line chemotherapy based at least
             one of the following criteria: ECOG performance status (PS) 2; Renal dysfunction
             (defined as creatinine-clearance <60 ml/min); Grade 2 peripheral neuropathy; Grade 2
             hearing loss (hearing loss measured by audiometry of 25 decibels at two contiguous
             frequencies).

          -  At least 1 measurable lesion by RECIST v1.1 not previously irradiated.

          -  Availability of an archival FFPE tumor tissue block from primary diagnosis specimen or
             metastatic specimen or 15 unstained slides (10 minimum). If an archived sample is not
             available, a fresh tumor biopsy must be performed.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. For UC
             patients, ECOG performance 2 is permitted (cisplatin ineligibility criterion)

        Exclusion Criteria:

          -  Prior immunotherapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40,
             anti-GITR, anti-LAG-3, anti-TIM-3 or anti-CTLA-4 antibody (including ipilimumab).

          -  Newly diagnosed brain metastases or known symptomatic brain metastases requiring
             steroids.

          -  Radiologically documented evidence of major blood vessel invasion or encasement by
             cancer or intratumor cavitation, regardless of tumor histology.

          -  Active autoimmune disease (that might deteriorate when receiving an immunostimulatory
             agent).

          -  Current use of immunosuppressive medication (except for those listed in protocol).

          -  Known prior severe hypersensitivity to the investigational products /monoclonal
             antibodies.

          -  Known history of immune-mediated colitis, inflammatory bowel disease, immune-mediated
             pneumonitis, pulmonary fibrosis.

          -  NCI CTCAE Grade 3 hemorrhage within 28 days prior to study enrollment.